Health Professionals
Oral Fluid
Place an Order
Prenatal Testing
New
Exclusively Available Through Dynacare
The first simple, objective blood test to identify Alzheimer’s disease
Intended for clinicians of patients undergoing a dementia workup, this test can help shorten the time to diagnose Alzheimer’s disease.
650,000 people in Canada are living with AD currently1
AD is the ninth leading cause of death in Canada2
Over the next 30 years, the number of people living with dementia in Canada will grow by 187%3
References:
Dynacare is the first company to make a fully blood-based ATN Profile available in Canada - giving physicians a simple, objective test for Alzheimer’s disease pathology so you can give patients and families clearer answers, take action and shorten time to diagnosis.
The ATN framework establishes a means for classifying biomarkers based on the biological evidence of Alzheimer’s disease that each marker provides1. These markers are divided into three categories to reflect the three primary biological changes associated with Alzheimer’s:
Amyloid Plaques
Accumulations of beta-amyloid 42 proteins begin to form plaques in the brain years before initial symptom onset.
Tau Tangles
The beta-amyloid 42 accumulation causes misfolding of tau proteins, which tangle into knots and disrupt normal brain cell function.
Assess levels of pathologic change consistent with Alzheimer’s disease
Neurodegeneration
Brain cell functional impairment causes the cells to die, which exacerbates the characteristic cognitive impairment symptoms observed in Alzheimer’s patients.
Assesses disease severity by measuring neurodegeneration
This is the first simple and non-invasive Alzheimer’s blood test that combines 3 Alzheimer’s biomarkers. The test is intended to be used by clinicians for patients who are suspected of possible dementia.
It identifies Alzheimer’s pathology to help make care, treatment and referral decisions.
Biological confirmation of disease is necessary for diagnosis. This test provides evidence of the biological changes that are consistent with Alzheimer’s disease.
However, Alzheimer’s still requires a clinical diagnosis based on clinical observation and cognitive testing.
Overall, the ATN framework for blood-based biomarkers can complement imaging and CSF analysis and create an opportunity for a more effective patient journey, and help accelerate the path to Alzheimer’s diagnosis.
The ATN Profile was clinically validated using 200 samples from a well-studied cohort in which all samples were characterized with patient age, sex, amyloid PET status, and clinical diagnosis. The beta-amyloid 42/40 ratio assay showed a ROC analysis area under the curve (AUC) of 0.944, with a sensitivity of 96% and specificity of 86.7%.
View Full ATN Profile
Download Neurology Requisition
View ATN Profile Brochure – Neurologists
View ATN Profile Brochure – Primary Care Physicians
View ATN Profile White Paper
Mental Health
OptimalRx Plus® tests 18 genes relevant for psychiatric treatment planning with the aim of choosing medications that reduce unwanted side effects and are more likely to be safe and effective.
Hematology
Dynacare has created a pathway for comprehensive hemoglobinopathy screening including molecular testing and genetic counselling for the province of Ontario.
Hereditary Cancer Screening
Hereditary cancer screening – including BRCA1 and BRCA2 –can help women and men understand their risk for the most common hereditary cancers, including breast, ovarian, colorectal, pancreatic and other cancers.
From scientists, customer service, information technology, specimen collection and transport teams, to quality testing, we combine all in one, offering you:
